[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589805":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":10,"responsibleParty":21,"collaborators":10,"id":23,"slug":24,"hasResults":25,"nctId":26,"briefTitle":27,"officialTitle":28,"acronym":29,"eligibilityCriteria":30,"healthyVolunteers":25,"sex":31,"minAge":32,"maxAge":33,"enrollmentInfo":34,"targetDuration":10,"studyType":37,"phases":10,"briefSummary":38,"conditions":39,"keywords":41,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":10},{"fullName":5,"class":6},"The First Affiliated Hospital of Bengbu Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Chronic Heart Failure Patients",null,"Participants diagnosed with chronic heart failure (CHF), classified based on left ventricular ejection fraction (LVEF) into heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF), or heart failure with preserved ejection fraction (HFpEF) groups. All participants receive standard-of-care heart failure management according to clinical guidelines. No investigational intervention is assigned; this is an observational cohort.",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Prof. Tang, Bi, PhD","CONTACT","86 0552-3086107","bitang2000@163.com",{"name":19,"role":15,"phone":16,"phoneExt":10,"email":20},"Dr. Cheng, Wenke, PhD","chengwenke@bbmu.edu.cn",{"type":22,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100589805","risk-stratification-via-hf-qrs-and-fibrosis-biomarkers-in-heart-failure-100589805",false,"NCT06959186","Risk Stratification Via HF-QRS and Fibrosis Biomarkers in Heart Failure","High-Frequency QRS and Fibrosis Biomarkers for Risk Stratification in Chronic Heart Failure: A Multicenter Prospective Cohort Study","STRIVE","Inclusion Criteria：\n\n1. Age ≥18 years and ≤85 years\n2. Diagnosis of chronic heart failure (CHF) based on ESC 2021 and AHA\u002FACC\u002FHFSA 2022 guidelines\n3. Presence of typical symptoms (e.g., exercise intolerance, dyspnea, orthopnea, paroxysmal nocturnal dyspnea, or fatigue) and signs (e.g., lower extremity edema, jugular venous distension, pulmonary rales)\n4. Elevated NT-proBNP (\\>125 pg\u002FmL, adjusted for BMI if \\>25 kg\u002Fm²)\n5. Evidence of structural or functional cardiac abnormalities by echocardiography (LVEF ≤50%, E\u002Fe' \\>14, e' \\\u003C9 cm\u002Fs, LV hypertrophy, or left atrial enlargement)\n6. For HFpEF patients (LVEF ≥50%), at least one additional echocardiographic abnormality is required\n\nThe Main Exclusion Criteria:\n\n1. End-stage renal disease requiring dialysis\n2. Severe chronic pulmonary disease (e.g., moderate-to-severe COPD, pulmonary fibrosis)\n3. Active malignancy or life expectancy \\\u003C1 year\n4. Severe anemia (Hb \\\u003C8 g\u002FdL) or uncontrolled thyroid dysfunction\n\n4\\. Cardiogenic shock or need for mechanical ventilatory support 5. Severe cognitive impairment, psychiatric illness, or inability to comply with study procedures 6. Other non-cardiac causes that may mimic heart failure symptoms (e.g., advanced liver cirrhosis)","ALL","18 Years","85 Years",{"count":35,"type":36},1500,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate whether high-frequency QRS (HF-QRS) signal parameters and circulating myocardial fibrosis biomarkers (such as PIIINP, Galectin-3, and sST2) can improve risk stratification in patients with chronic heart failure (CHF). In this prospective, multicenter cohort study (STRIVE cohort), patients with CHF will be enrolled and followed for 18 months. Clinical data, routine heart function measures (such as NT-proBNP and LVEF), HF-QRS features from standard 12-lead ECG, and serum fibrosis biomarker levels will be collected. The study will assess the association of HF-QRS abnormalities and fibrosis biomarker levels with major clinical outcomes, including cardiovascular mortality, first heart failure-related rehospitalization, malignant arrhythmia events, all-cause rehospitalization and mortality. By integrating electrophysiological and molecular markers, this research aims to develop a novel, non-invasive predictive model to support early risk identification and personalized management of heart failure patients.",[40],"Heart Failure",[40,42,43,44,45,46],"Myocardial Fibrosis","high-frequency QRS","biomarker","rehospitalization","mortality","NOT_YET_RECRUITING","2025-04-28",{"date":50,"type":51},"2025-05-06","ACTUAL",{"date":53,"type":36},"2025-06-30",{"date":55,"type":36},"2026-12-31",{"name":5,"class":6}]